BiotechTube

SHR-1314 + Placebo

Phase 3UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-Severe Plaque Psoriasis

Conditions

Moderate-to-Severe Plaque Psoriasis

Trial Timeline

Apr 25, 2021 → Aug 30, 2023

NCT ID
NCT04839016

About SHR-1314 + Placebo

SHR-1314 + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Moderate-to-Severe Plaque Psoriasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04839016. Target conditions include Moderate-to-Severe Plaque Psoriasis.

What happened to similar drugs?

2 of 8 similar drugs in Moderate-to-Severe Plaque Psoriasis were approved

Approved (2) Terminated (0) Active (6)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅dupilumabSanofiApproved
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
🔄PonesimodVanda PharmaceuticalsPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3
🔄Zalviso™ 15 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04839016Phase 3UNKNOWN
NCT03463187Phase 1/2Completed

Competing Products

13 competing products in Moderate-to-Severe Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiApproved
43
dupilumabSanofiPre-clinical
26
PonesimodVanda PharmaceuticalsPhase 3
37
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30